Alzheimer’s Disease (AD) remains a diagnostically challenging disease for providers. Just a little over two decades ago, the diagnosis of AD was made through autopsy. Today, pathology is much better understood, and diagnosis is often made through a combination of clinical signs, biomarkers in cerebrospinal fluid (CSF), and amyloid PET scans.

New disease-modifying treatments have been shown to impact the underlying AD pathology but are likely most beneficial in early AD.

These blood-based biomarkers used in a ratio are highly concordant with CSF measurements and amyloid PET imaging and may lead to improvements in early AD diagnosis. These biomarkers could also advance the development and implementation of disease-modifying treatments in the field of AD and related disorders.

Planned and developed by Medavera, Inc. and supported by an educational grant from Fujirebio Diagnostics, Inc.